|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...2425262728293031323334...4950» |
- Trial completion: Treatment for Depression Among HIV-Infected Youth (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=42, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed
- | darunavir/ritonavir / Generic mfg.
Trial completion, Head-to-Head: RADAR: Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. (clinicaltrials.gov) - Jan 20, 2014
P3, N=100, Completed, Sponsor: Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Comparison of HIV Testing Algorithms (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=495, Completed, Sponsor: Medecins Sans Frontieres
Active, not recruiting --> Completed N=400 --> 495
- Enrollment change: An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment (clinicaltrials.gov) - Jan 19, 2014
P2, N=7, Completed, Sponsor: Achillion Pharmaceuticals
N=400 --> 495 N=25 --> 7
- ||| tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants (clinicaltrials.gov) - Jan 19, 2014
P2, N=76, Completed, Sponsor: Achillion Pharmaceuticals
N=25 --> 7 N=60 --> 76
- Enrollment closed: BIDMED: Brief Intervention for Drug Misuse in the Emergency Department (clinicaltrials.gov) - Jan 19, 2014
P2, N=1100, Active, not recruiting, Sponsor: Rhode Island Hospital
N=60 --> 76 Recruiting --> Active, not recruiting
- Trial completion: Comparison of HIV Testing Algorithms (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=495, Completed, Sponsor: Medecins Sans Frontieres
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment (clinicaltrials.gov) - Jan 19, 2014
P2, N=7, Completed, Sponsor: Achillion Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM). (clinicaltrials.gov) - Jan 18, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART (clinicaltrials.gov) - Jan 18, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || lopinavir/ritonavir / Generic mfg.
Enrollment change: Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=236, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=600 --> 236
- | GTU-multi-HIV B clade DNA vaccine / ValiRx
New P1/2 trial: Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers (clinicaltrials.gov) - Jan 15, 2014
P1/2, N=92, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=236, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=600 --> 236 Active, not recruiting --> Completed
- mesalamine extended-release capsules / Generic mfg.
Trial completion: Mesalamine to Reduce T Cell Activation in HIV Infection (clinicaltrials.gov) - Jan 15, 2014
P4, N=30, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Trial completion, IO biomarker: Kidney and Liver Transplantation in People With HIV (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=275, Completed, Sponsor: University of California, San Francisco
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Trial withdrawal: RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) (clinicaltrials.gov) - Jan 14, 2014
P1, N=0, Withdrawn, Sponsor: Atlantic Health System
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) (clinicaltrials.gov) - Jan 14, 2014
P1, N=0, Withdrawn, Sponsor: Atlantic Health System
Recruiting --> Withdrawn N=10 --> 0
- ||| Enrollment open: Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=1200, Recruiting, Sponsor: Gen-Probe, Incorporated
N=10 --> 0 Not yet recruiting --> Recruiting
- Enrollment open, Adherence: SPARK: Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=445, Recruiting, Sponsor: Hunter College
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || nevirapine / Generic mfg.
Enrollment change: Non-interventional Observational Study With Viramune (clinicaltrials.gov) - Jan 12, 2014
P=N/A, N=265, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=342 --> 265
- ||| vicriviroc (MK-7690) / Merck (MSD)
Enrollment change: Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) (clinicaltrials.gov) - Jan 12, 2014
P2, N=111, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=342 --> 265 N=150 --> 111
- | New P1 trial: Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study (clinicaltrials.gov) - Jan 12, 2014
P1, N=12, Recruiting, Sponsor: Ottawa Hospital Research Institute
- ||| nevirapine / Generic mfg.
Trial completion: Non-interventional Observational Study With Viramune (clinicaltrials.gov) - Jan 12, 2014
P=N/A, N=265, Completed, Sponsor: Boehringer Ingelheim
N=150 --> 111 Active, not recruiting --> Completed
- |||||||||| daclatasvir/sofosbuvir / Generic mfg.
New P3 trial, Combination therapy, IO biomarker: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (clinicaltrials.gov) - Jan 8, 2014
P3, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| nevirapine / Generic mfg.
Trial completion: Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients (clinicaltrials.gov) - Jan 8, 2014
P=N/A, N=600, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: HIV-VAC: Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection (clinicaltrials.gov) - Jan 7, 2014
P1, N=11, Completed, Sponsor: Gitte Kronborg
Active, not recruiting --> Completed N=20 --> 11
- Enrollment closed: Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=500, Active, not recruiting, Sponsor: University of California, Los Angeles
N=20 --> 11 Recruiting --> Active, not recruiting
- Trial completion: HIV-VAC: Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection (clinicaltrials.gov) - Jan 7, 2014
P1, N=11, Completed, Sponsor: Gitte Kronborg
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- || lopinavir/ritonavir / Generic mfg.
Enrollment change, Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=240, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Completed N=160 --> 240
- ||||| Enrollment change: PRINCE1: PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (clinicaltrials.gov) - Jan 6, 2014
P3, N=82, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=160 --> 240 N=56 --> 82
- ||||| VCL-HB01 / Fresh Tracks Therap
New P1/2 trial: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults (clinicaltrials.gov) - Jan 6, 2014
P1/2, N=156, Recruiting, Sponsor: Vical
- Trial completion: Effects of Treatment With Aprepitant (Emend (clinicaltrials.gov) - Jan 6, 2014
P1, N=18, Completed, Sponsor: University of Pennsylvania
N=56 --> 82 Recruiting --> Completed
- Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals (clinicaltrials.gov) - Jan 6, 2014
P4, N=232, Completed, Sponsor: University of Pennsylvania
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa (clinicaltrials.gov) - Jan 5, 2014
P4, N=1206, Completed, Sponsor: Medical Research Council
- Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics
New P3 trial: Compassionate Use of Ibalizumab for the Treatment of HIV Infection (clinicaltrials.gov) - Jan 5, 2014
P3, N=0, Available, Sponsor: University of Colorado, Denver
- Trial completion: A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=450, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Discordant: EPIC: Enhanced Prevention in Couples: Feasibility Study #2 (clinicaltrials.gov) - Jan 2, 2014
P=N/A, N=191, Active, not recruiting, Sponsor: Columbia University
- | Vocabria (cabotegravir oral) / ViiV Healthcare
New P1 trial: Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction (clinicaltrials.gov) - Jan 2, 2014
P1, N=42, Recruiting, Sponsor: ViiV Healthcare
- Trial initiation date: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Dec 29, 2013
P=N/A, N=324, Recruiting, Sponsor: FHI 360
Active, not recruiting --> Completed Initiation date: Jul 2013 --> Nov 2013
- Enrollment open: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Dec 29, 2013
P=N/A, N=324, Recruiting, Sponsor: FHI 360
Initiation date: Jul 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) (clinicaltrials.gov) - Dec 29, 2013
P2, N=30, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects (clinicaltrials.gov) - Dec 29, 2013
P2, N=44, Completed, Sponsor: Margaret A. Fischl, M.D.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Biomarker, Enrollment open: EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=50, Recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) (clinicaltrials.gov) - Dec 22, 2013
P1, N=18, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: Leukapheresis for Research on HCV-Coinfected Patients (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=500 --> 700
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Enrollment open, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Dec 19, 2013
P1, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=500 --> 700 Active, not recruiting --> Recruiting
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects (clinicaltrials.gov) - Dec 18, 2013
P1, N=43, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | New P2 trial: A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts (clinicaltrials.gov) - Dec 17, 2013
P2, N=299, Completed, Sponsor: University of Aberdeen
- |||| Intelence (etravirine) / J&J
Trial completion, Combination therapy, IO biomarker: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients (clinicaltrials.gov) - Dec 15, 2013
P4, N=220, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: PCV13HIV2011: Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults (clinicaltrials.gov) - Dec 12, 2013
P3, N=50, Completed, Sponsor: University of Siena